Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

Jounce Therapeutics logo

About Jounce Therapeutics Stock (NASDAQ:JNCE)

Advanced Chart

Key Stats

Today's Range
$1.88
$1.88
50-Day Range
$1.84
$1.94
52-Week Range
$0.58
$5.87
Volume
169,314 shs
Average Volume
2.46 million shs
Market Capitalization
$98.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

JNCE Stock Analysis - Frequently Asked Questions

Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.15.

Jounce Therapeutics (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/04/2021
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:JNCE
CIK
1640455
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.92 million
Net Margins
N/A
Pretax Margin
-61.93%
Return on Equity
-30.90%
Return on Assets
-26.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.37
Quick Ratio
8.37

Sales & Book Value

Annual Sales
$82 million
Price / Sales
1.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.54 per share
Price / Book
0.53

Miscellaneous

Outstanding Shares
52,630,000
Free Float
48,993,000
Market Cap
$98.94 million
Optionable
Optionable
Beta
0.75

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:JNCE) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners